Homrich & Berg Sells 3,019 Shares of Pfizer (PFE)

Homrich & Berg lessened its holdings in shares of Pfizer (NYSE:PFE) by 2.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 119,580 shares of the biopharmaceutical company’s stock after selling 3,019 shares during the quarter. Homrich & Berg’s holdings in Pfizer were worth $4,331,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of PFE. Security Asset Management lifted its holdings in Pfizer by 6.1% in the fourth quarter. Security Asset Management now owns 22,827 shares of the biopharmaceutical company’s stock valued at $827,000 after buying an additional 1,317 shares during the period. Waldron LP lifted its holdings in Pfizer by 6.0% in the fourth quarter. Waldron LP now owns 23,785 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 1,341 shares during the period. Community Financial Services Group LLC lifted its holdings in Pfizer by 0.6% in the fourth quarter. Community Financial Services Group LLC now owns 216,884 shares of the biopharmaceutical company’s stock valued at $7,856,000 after buying an additional 1,375 shares during the period. TCI Wealth Advisors Inc. lifted its holdings in Pfizer by 2.0% in the fourth quarter. TCI Wealth Advisors Inc. now owns 71,284 shares of the biopharmaceutical company’s stock valued at $2,582,000 after buying an additional 1,375 shares during the period. Finally, Banced Corp lifted its holdings in Pfizer by 5.4% in the fourth quarter. Banced Corp now owns 26,667 shares of the biopharmaceutical company’s stock valued at $965,000 after buying an additional 1,376 shares during the period. Institutional investors own 71.57% of the company’s stock.

PFE opened at $35.50 on Friday. Pfizer has a 1-year low of $31.67 and a 1-year high of $39.43. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $209.36 billion, a price-to-earnings ratio of 13.40, a P/E/G ratio of 1.75 and a beta of 0.89.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.03. Pfizer had a net margin of 41.29% and a return on equity of 25.96%. The firm had revenue of $12.91 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same period in the previous year, the firm posted $0.69 earnings per share. The business’s revenue was up 1.0% compared to the same quarter last year. equities analysts predict that Pfizer will post 2.95 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.83%. The ex-dividend date is Thursday, May 10th. Pfizer’s payout ratio is presently 51.32%.

Several research firms recently issued reports on PFE. Morningstar set a $43.50 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, May 2nd. DZ Bank restated a “sell” rating on shares of Pfizer in a report on Thursday, May 3rd. JPMorgan Chase set a $42.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, May 8th. ValuEngine lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, BMO Capital Markets dropped their target price on shares of Pfizer from $43.00 to $42.00 and set an “outperform” rating on the stock in a report on Wednesday, May 2nd. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company. Pfizer presently has an average rating of “Hold” and an average price target of $39.57.

In other news, CEO Ian C. Read sold 132,312 shares of the business’s stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total transaction of $4,764,555.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the sale, the insider now directly owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. Over the last three months, insiders have sold 380,349 shares of company stock valued at $13,829,340. 0.06% of the stock is currently owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply